Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026)

Lantheus Holdings (LNTH) reported Net Income towards Common Stockholders of $118.4 million for Q1 2026, up 62.34% year-over-year from $72.9 million in Q1 2025, and up 118.93% quarter-over-quarter from $54.1 million in Q4 2025.

Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has 13 years of Net Income towards Common Stockholders data on file, last reported at $118.4 million in Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at $118.4 million, up 62.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $279.0 million (up 9.72% YoY), and the FY2025 annual result was $233.6 million, down 25.25% from the prior year.
  • Net Income towards Common Stockholders grew to $118.4 million in Q1 2026 per LNTH's latest filing, from $54.1 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $132.0 million in Q3 2023 and troughed at -$119.2 million in Q4 2022.
  • A 5-year average of $59.9 million and a median of $62.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders plunged 196.37% in 2022, then jumped 4769.26% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$119.2 million in 2022, then surged by 186.74% to $103.4 million in 2023, then slumped by 111.4% to -$11.8 million in 2024, then soared by 558.76% to $54.1 million in 2025, then soared by 118.93% to $118.4 million in 2026.
  • Business Quant data shows LNTH's Net Income towards Common Stockholders at $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 366.00 Mn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 274.90 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 1.99 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 197.90 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn -66.53 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 118.42 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn -92.12 Mn
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn 52.88 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 118.42 Mn
Dec 31, 2025 54.09 Mn
Sep 30, 2025 27.77 Mn
Jun 30, 2025 78.76 Mn
Mar 31, 2025 72.95 Mn
Dec 31, 2024 -11.79 Mn
Sep 30, 2024 131.09 Mn
Jun 30, 2024 62.07 Mn
Mar 31, 2024 131.07 Mn
Dec 31, 2023 103.38 Mn
Sep 30, 2023 131.96 Mn
Jun 30, 2023 94.13 Mn
Mar 31, 2023 -2.81 Mn
Dec 31, 2022 -119.19 Mn
Sep 30, 2022 61.23 Mn
Jun 30, 2022 43.06 Mn
Mar 31, 2022 42.96 Mn
Dec 31, 2021 -40.22 Mn
Sep 30, 2021 -13.42 Mn
Jun 30, 2021 -26.66 Mn